{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T08:17:48Z","timestamp":1783325868344,"version":"3.54.6"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"\n Objective<\/jats:title>\n Voriconazole (VRC) is widely used as an antifungal agent, yet its potential to cause drug-induced liver injury (DILI) remains a major clinical concern. Therefore, this study aims to identify the relevant risk factors for VRC-induced DILI, construct a predictive model using LASSO-Logistic regression, and present it as a nomogram. Additionally, a web-based prediction tool was developed to facilitate clinical application, ultimately providing a scientific basis for early risk assessment of DILI in patients receiving VRC therapy.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Clinical data of inpatients who received VRC for the treatment or prophylaxis of fungal infections at the First People\u2019s Hospital of Changzhou from March 2022 to June 2025 were collected retrospectively. The patients were divided into a DILI group and a non-DILI group according to the diagnostic criteria for DILI. Univariate analysis was used to screen for variables with intergroup differences, followed by LASSO regression for further feature optimization. The screened variables were incorporated into a multivariate Logistic regression to construct a nomogram prediction model for DILI. The receiver operating characteristic (ROC) curve, calibration curve and decision curve analysis (DCA) were adopted to evaluate the discrimination, calibration and clinical applicability of the model, with the Bootstrap method for internal validation. Additionally, a web-based interactive prediction calculator was developed based on R Shiny.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 250 patients were enrolled, among whom 47 developed DILI. Univariate analysis revealed statistically significant differences between the DILI group and the non-DILI group in seven variables, namely renal replacement therapy, concomitant bacterial infection, steady-state trough concentration of VRC (C-\n VRC<\/jats:sub>\n ), C-\n VRC<\/jats:sub>\n \/daily dose (C-\n VRC<\/jats:sub>\n \/DD), the ratio of C-\n VRC<\/jats:sub>\n to VRC N-oxide concentration (C-\n VRC<\/jats:sub>\n \/C-\n VNO<\/jats:sub>\n , MR), albumin (ALB) and serum creatinine (Scr) (all\n P<\/jats:italic>\n &lt; 0.05). LASSO regression further identified five variables associated with VRC-induced DILI: concomitant bacterial infection, C-\n VRC<\/jats:sub>\n , MR, ALB and Scr. Multivariate Logistic regression analysis demonstrated that C-\n VRC<\/jats:sub>\n , MR, ALB and Scr were independent risk factors for VRC-induced DILI (all\n P<\/jats:italic>\n &lt; 0.05). A nomogram prediction model was constructed based on the above factors, with the area under the ROC curve (AUC) of 0.818 (95% confidence interval [CI]: 0.748\u20130.888). The calibration curve showed a good fit between the predicted values and actual observed values of the model. DCA indicated that the model yielded favorable clinical net benefits within a certain range of threshold probabilities, and the Bootstrap method verified the good stability of the model. The developed web-based calculator enables the calculation of DILI risk probability in individual patients.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n C-\n VRC<\/jats:sub>\n , MR, ALB and Scr are important predictors of VRC-induced DILI. The nomogram prediction model constructed based on LASSO-logistic regression has good predictive performance and clinical applicability, and the developed web-based interactive prediction calculator improves the clinical convenience of the model. This model can be effectively used for the early risk assessment of DILI in patients receiving VRC, providing support for clinical individualized medication and risk prevention and control.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fphar.2026.1857552","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T07:46:47Z","timestamp":1783324007000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Incorporating the metabolic ratio (C-VRC\/C-VNO) into a LASSO-logistic model for predicting voriconazole-induced DILI: development and web-based implementation"],"prefix":"10.3389","volume":"17","author":[{"given":"Jing","family":"Ling","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The First People\u2019s Hospital of Changzhou\/The Third Affiliated Hospital of Soochow University","place":["Changzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueling","family":"Fu","sequence":"additional","affiliation":[{"name":"School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuping","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First People\u2019s Hospital of Changzhou\/The Third Affiliated Hospital of Soochow University","place":["Changzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First People\u2019s Hospital of Changzhou\/The Third Affiliated Hospital of Soochow University","place":["Changzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First People\u2019s Hospital of Changzhou\/The Third Affiliated Hospital of Soochow University","place":["Changzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First People\u2019s Hospital of Changzhou\/The Third Affiliated Hospital of Soochow University","place":["Changzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.2147\/DDDT.S475706","article-title":"The role of plasma trough concentration of voriconazole and voriconazole N-Oxide in its hepatotoxicity in adult patients","volume":"18","author":"Cheng","year":"2024","journal-title":"Drug Des. Devel Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"105871","DOI":"10.1016\/j.yrtph.2025.105871","article-title":"Mechanism and marker of voriconazole-induced liver injury: insights from a quantitative systems toxicology approach","volume":"162","author":"Du","year":"2025","journal-title":"Regul. Toxicol. Pharm."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1007\/s11096-025-01946-8","article-title":"Establishment and validation of a predictive nomogram for voriconazole-associated liver injury in lung transplant patients","volume":"47","author":"Du","year":"2025","journal-title":"Int. J. Clin. Pharm-Net"},{"key":"B4","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1345\/aph.1H671","article-title":"Adverse effects of voriconazole: analysis of the French pharmacovigilance database","volume":"41","author":"Eiden","year":"2007","journal-title":"Ann. Pharmacother."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1688711","DOI":"10.3389\/fphar.2025.1688711","article-title":"Voriconazole-associated liver injury: clinical risk factor identification and predictive nomogram construction","volume":"16","author":"Feng","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1097\/FTD.0000000000000095","article-title":"Determination of plasma unbound fraction of voriconazole in patients treated with a prophylactic or a curative treatment","volume":"36","author":"Florent","year":"2014","journal-title":"Ther. Drug Monit."},{"key":"B7","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.ijantimicag.2006.01.003","article-title":"Clinical pharmacokinetics of voriconazole","volume":"27","author":"Leveque","year":"2006","journal-title":"Int. J. Antimicrob. Ag."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1726902","DOI":"10.3389\/fphar.2025.1726902","article-title":"Study on the correlation between plasma concentration of voriconazole and clinical efficacy and safety in elderly patients","volume":"16","author":"Li","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1111\/bcp.13595","article-title":"Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients","volume":"84","author":"Lin","year":"2018","journal-title":"Brit. J. Clin. Pharm."},{"key":"B10","doi-asserted-by":"publisher","first-page":"709","DOI":"10.16718\/j.1009-7708.2023.06.007","article-title":"The status of therapeutic drug monitoring and voriconazole-induced liver injury and its influencing factors","volume":"6","author":"Lin","year":"2023","journal-title":"Chin. J. Infect. Chemother."},{"key":"B11","first-page":"2906","article-title":"Construction and validation of a risk prediction model for voriconazole-induced liver injury","volume":"20","author":"Liu","year":"2022","journal-title":"J. Central South Pharm."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e48725","DOI":"10.1128\/aac.00487-25","article-title":"Voriconazole-induced liver injury: incidence patterns and risk factors in a retrospective cohort","volume":"69","author":"Lou","year":"2025","journal-title":"Antimicrob. Agents Ch."},{"key":"B13","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3760\/cma.j.cn501113-20230419-00176","article-title":"Standardize the diagnosis and treatment of drug-induced liver injury, and strengthen clinical and translational research","volume":"31","author":"Mao","year":"2023","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"B14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ijantimicag.2009.01.008","article-title":"Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes","volume":"34","author":"Matsumoto","year":"2009","journal-title":"Int. J. Antimicrob. Ag."},{"key":"B15","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.ijantimicag.2009.12.021","article-title":"Monitoring plasma voriconazole levels following intravenous administration in critically ill patients: an observational study","volume":"35","author":"Myrianthefs","year":"2010","journal-title":"Int. J. Antimicrob. Ag."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e130336","DOI":"10.5812\/ijpr-130336","article-title":"Hepatotoxicity induced by azole antifungal agents: a review Study","volume":"22","author":"Rakhshan","year":"2023","journal-title":"Iran. J. Pharm. Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1625003","DOI":"10.3389\/fphar.2025.1625003","article-title":"Risk factors for voriconazole-associated hepatotoxicity in patients with liver dysfunction: a retrospective nested case-control study","volume":"16","author":"Ren","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.cca.2013.05.025","article-title":"Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity","volume":"424","author":"Suzuki","year":"2013","journal-title":"Clin. Chim. Acta"},{"key":"B20","doi-asserted-by":"publisher","first-page":"62","DOI":"10.22037\/ijpr.2020.112330.13688","article-title":"Association of Voriconazole trough plasma concentration with efficacy and incidence of hepatotoxicity in Iranian patients with hematological malignancies","volume":"20","author":"Taghvaye-Masoumi","year":"2021","journal-title":"Iran. J. Pharm. Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1111\/bcp.14578","article-title":"Population pharmacokinetics, safety and dosing optimization of voriconazole in patients with liver dysfunction: a prospective observational study","volume":"87","author":"Tang","year":"2021","journal-title":"Brit. J. Clin. Pharm."},{"key":"B22","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3233\/SHTI230979","article-title":"Construction of a prediction model for voriconazole-induced hepatotoxicity based on mixed-effects random Forest","volume":"310","author":"Tong","year":"2024","journal-title":"Stud. Health Technol. Inf."},{"key":"B23","doi-asserted-by":"publisher","first-page":"6782","DOI":"10.1128\/AAC.03641-14","article-title":"Impact of hypoalbuminemia on voriconazole pharmacokinetics in critically ill adult patients","volume":"58","author":"Vanstraelen","year":"2014","journal-title":"Antimicrob. Agents Ch."},{"key":"B24","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1002\/phar.1779","article-title":"Risk factors for voriconazole-associated hepatotoxicity in patients in the intensive care unit","volume":"36","author":"Wang","year":"2016","journal-title":"Pharmacotherapy"},{"key":"B25","unstructured":"The application study of voriconazole and its metabolites concentration monitoring in allogeneic hematopoietic stem cell transplantation patients\n \n 945\n 951\n \n \n Wang\n H.\n \n \n Wang\n L.\n \n \n Li\n M.\n \n \n Shi\n L.\n \n \n Sun\n H.\n \n \n Liu\n H.\n \n \n 32\n 2024"},{"key":"B26","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3390\/ph17060665","article-title":"Renal replacement therapy as a new indicator of voriconazole clearance in a population pharmacokinetic analysis of critically ill patients","volume":"17","author":"Wang","year":"2024","journal-title":"Pharmaceuticals-Base"},{"key":"B27","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3760\/cma.j.cn112150-20220117-00063","article-title":"Application of LASSO and its extended method in variable selection of regression analysis","volume":"57","author":"Xi","year":"2023","journal-title":"Zhonghua Yu Fang. Yi Xue Za Zhi"},{"key":"B28","doi-asserted-by":"publisher","first-page":"4254","DOI":"10.3390\/jcm12134254","article-title":"The development and validation of a predictive model for voriconazole-related liver injury in hospitalized patients in China","volume":"12","author":"Xiao","year":"2023","journal-title":"J. Clin. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1683370","DOI":"10.3389\/fmed.2025.1683370","article-title":"Drug-induced liver injury highly probable due to goserelin: a case report evaluated with the updated RUCAM (2016)","volume":"12","author":"Xiao","year":"2025","journal-title":"Front. Med-Lausanne"},{"key":"B30","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1111\/myc.13293","article-title":"The influence of CYP2C19 polymorphisms on voriconazole trough concentrations: systematic review and meta-analysis","volume":"64","author":"Zhang","year":"2021","journal-title":"Mycoses"},{"key":"B31","doi-asserted-by":"publisher","first-page":"4521997","DOI":"10.1155\/JCPT\/4521997","article-title":"Population pharmacokinetic and pharmacodynamic analysis of voriconazole\u2010induced liver injury in Chinese lung transplant patients","volume":"2026","author":"Zhang","year":"2026","journal-title":"J. Clin. Pharm. Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"891336","DOI":"10.3389\/fphar.2022.891336","article-title":"Antifungal drugs and drug-induced liver injury: a real-world study leveraging the FDA adverse event reporting system database","volume":"13","author":"Zhou","year":"2022","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1857552\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T07:46:56Z","timestamp":1783324016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1857552\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":32,"alternative-id":["10.3389\/fphar.2026.1857552"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1857552","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"article-number":"1857552"}}